Hemin for injection - Biologic Drug Details

Summary for hemin for injection

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for hemin for injection Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for hemin for injection Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for hemin for injection Derived from Patent Text Search

No patents found based on company disclosures

Hemin for injection Market Analysis and Financial Projection

Last updated: February 16, 2026

What Are the Market Dynamics for Hemin for Injection?

Hemin for injection is a purified form of hemin, a heme derivative used primarily to treat acute porphyrias, namely acute intermittent porphyria (AIP). Its market is influenced by disease prevalence, regulatory status, and manufacturing capacity.

Disease Prevalence and Demand Drivers

• Acute Intermittent Porphyria (AIP): The rarity of AIP limits overall market size. Estimated prevalence is approximately 5 per 100,000 globally, with higher rates in certain populations, such as Northern Europe and some Mediterranean regions.
• Treatment Need: Hemin is indicated for acute attacks; the number of annual attacks per patient varies. Typically, patients experience 1-4 attacks annually.
• Alternative Treatments: Other options include carbohydrate loading and symptomatic management, though hemin remains the only specific approved therapy in many jurisdictions.

Regulatory Landscape and Market Access

• Approval Status: Hemin for injection has received regulatory approval in major markets such as the US (FDA), Europe (EMA), and Japan. Variations in supply and labeling impact market access.
• Reimbursement: Insurance and government healthcare programs cover hemin in regions like the US and Europe; however, reimbursement levels impact pricing strategies.

Manufacturing and Supply Chain

• Limited Production: Hemin production involves complex fermentation and extraction processes; only a few manufacturers globally operate at scale.
• Supply Constraints: Historically, supply shortages have affected availability, notably following manufacturing issues or regulatory delays.

Competitive Environment

• Market Players: Alnylam Pharmaceuticals, Recordati Rare Diseases, and other specialty pharma companies dominate the market, with formulations from Fresenius Kabi and Recordati being most prevalent.
• Emerging Competitors: Biosynthetic or recombinant alternatives are under research but are not yet commercialized.

What Is the Financial Trajectory for Hemin for Injection?

Financial outlooks depend on market size, pricing strategies, and clinical pipeline developments.

Revenue Estimates

• Current Market Size: The global hemin market is estimated at around $100-150 million in 2022, projected to grow at a compound annual growth rate (CAGR) of 4-6%.
• Pricing: List prices range from $4,000 to $6,000 per vial in the US; actual reimbursement varies. The high price stems from complex manufacturing and limited competition.

Factors Influencing Growth

• Increasing Diagnosis: Improved awareness and diagnosis of AIP could increase demand marginally.
• Enhanced Access and Supply Stability: Prevention of shortages could boost utilization rates.
• Pricing Trends: Ongoing negotiations with payers and policy changes could pressure margins, especially as biosimilars or generics enter the market.

Pipeline and Future Revenue Prospects

• New Formulations and Indications: Research into alternative delivery methods or broader indications (e.g., other porphyrias) could expand market size.
• Biosimilars and Competition: Entry of biosimilar hemin could reduce prices, impacting revenue growth.

Investment Outlook

• Growth Opportunities: Limited due to disease rarity but steady owing to existing approval and infrastructure.
• Risks: Manufacturing bottlenecks, regulatory delays, or emergence of alternative therapies pose risks to financial stability.

Key Takeaways

• Hemin for injection is a niche but essential treatment in acute porphyria management, with limited but steady demand.
• The market is characterized by supply constraints, high pricing, and limited competitors.
• Market growth relies on increased diagnosis, stable supply, and possible expansion into other indications.
• Revenue prospects are moderate, with potential downside from biosimilar competition and policy pressures.
• Companies with manufacturing expertise and strong regulatory relationships maintain competitive advantage.

FAQs

1. What is the primary use of hemin for injection? It treats acute attacks of porphyria, especially AIP, by reducing the accumulation of porphyrin precursors.

2. How large is the global market for hemin? Estimated at $100-150 million as of 2022, with moderate growth prospects.

3. What are the main factors impacting supply? Complex manufacturing, limited producers, and regulatory compliance issues.

4. Are there biosimilars available for hemin? No. Biosimilar competition has not yet entered the market; however, it remains a potential future development.

5. What are regulatory challenges for hemin products? Ensuring manufacturing consistency, managing supply chain disruptions, and obtaining market approvals across territories.

---

Sources

[1] Alnylam Pharmaceuticals. Hemin market data, 2022.

[2] EvaluatePharma. Hemin and porphyria treatments, 2022.

[3] FDA. Hemin for injection approval and label, 2020.

[4] EMA. European Medicines Agency marketing authorization, 2019.

[5] MarketWatch. Rare disease therapeutics market report, 2022.